Rallybio Corporation (NASDAQ:RLYB) Shares Set to Pay Special Dividend of $13.56

Rallybio Corporation (NASDAQ:RLYB) declared a special dividend on Sunday, October 25th. Stockholders of record on Thursday, November 5th will be paid a dividend of $13.56 per share on Friday, November 13th.

Rallybio Stock Performance

Rallybio stock traded down $0.72 during trading on Tuesday, reaching $15.93. 52,619 shares of the company’s stock were exchanged, compared to its average volume of 123,699. The company’s 50-day moving average is $16.82 and its two-hundred day moving average is $12.67. Rallybio has a 52-week low of $3.67 and a 52-week high of $17.57. The firm has a market cap of $84.59 million, a price-to-earnings ratio of -3.67 and a beta of -0.72.

Rallybio (NASDAQ:RLYB) last released its quarterly earnings data on Tuesday, October 27th. The company reported ($0.48) EPS for the quarter. Rallybio had a negative net margin of 911.07% and a negative return on equity of 40.53%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on RLYB shares. Weiss Ratings raised shares of Rallybio from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, October 6th. Wall Street Zen upgraded Rallybio from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. One research analyst has rated the stock with a Hold rating. According to data from MarketBeat.com, Rallybio has a consensus rating of “Hold”.

Rallybio Company Profile

Rallybio Corporation is a clinical-stage biotechnology company focused on developing medicines for patients with rare diseases, with an emphasis on conditions that affect maternal and fetal health, as well as other serious disorders with limited treatment options. The company is headquartered in New Haven, Connecticut, and its programs are intended for specialized patient populations in the United States and international markets.

Rallybio’s lead program, RLYB212, is being developed to prevent fetal and neonatal alloimmune thrombocytopenia, a rare condition in which maternal antibodies attack fetal platelets during pregnancy.